Skip to content

Bain Capital Life Sciences Investors, LLC

Follow

13F filer, CIK 1703031, Boston, MA

Bain Capital Life Sciences Investors, LLC reported $1,489,841,174 across 23 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 81.87% of the portfolio.

Accepted , ingested 13F-HR 0001193125-26-462089

Period
2026-09-30
Reported value
$1.49B
Holdings
23
Top 10 weight
81.87%
New
4
Sold out
2

Part of the filer group Bain Capital Life Sciences Investors, LLC

How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SGRY SURGERY PARTNERS INC: 13D/A 30,055,197 shares, 22.96% of the class, 13D/A filed 2026-10-26, 0001193125-26-431228Timeline
    Accepted , ingested
  • ADCT ADC THERAPEUTICS SA: 13G 14,825,625 shares, 9.99% of the class, 13G filed 2026-10-29, 0001193125-26-438199Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ADRXnew+6,728,970$134M
TARSnew+1,096,141$86.2M
ALKSadded+1,213,047$49.2M
FRNMnew+2,365,459$37.3M
DYNnew+1,900,000$30.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
HTFLreduced-4,000,000-$199M
DNTHexited-362,470-$35.3M
KYTXreduced-1,573,000-$10.7M
PHVSreduced-200,000-$6.21M
UPBexited-600,949-$4.16M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-462089, largest first. % of portfolio is the value over $1,489,841,174, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 22,583,268 shares; 2026Q3: 22,583,268 shares 22,583,268$258M17.31%0Timeline
HTFLHEARTFLOW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 12,448,158 shares; 2025Q4: 12,448,158 shares; 2026Q1: 10,448,158 shares; 2026Q2: 8,448,158 shares; 2026Q3: 4,448,158 shares 4,448,158$221M14.85%-4,000,000Timeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 6,728,970 shares 6,728,970$134M9.01%newTimeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 610,000 shares; 2026Q2: 1,937,938 shares; 2026Q3: 3,150,985 shares 3,150,985$128M8.57%+1,213,047Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 10,719,110 shares; 2025Q1: 10,719,110 shares; 2025Q2: 10,719,110 shares; 2025Q3: 10,719,110 shares; 2025Q4: 7,306,566 shares; 2026Q1: 7,306,566 shares; 2026Q2: 3,806,566 shares; 2026Q3: 3,806,559 shares 3,806,559$92.6M6.21%-7Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 14,565,457 shares; 2025Q1: 17,600,621 shares; 2025Q2: 17,600,621 shares; 2025Q3: 17,600,621 shares; 2025Q4: 17,600,621 shares; 2026Q1: 17,600,621 shares; 2026Q2: 17,600,621 shares; 2026Q3: 17,600,621 shares 17,600,621$90.8M6.1%0Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,096,141 shares 1,096,141$86.2M5.78%newTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,303,381 shares; 2025Q1: 3,303,381 shares; 2025Q2: 3,303,381 shares; 2025Q3: 3,181,275 shares; 2025Q4: 2,802,081 shares; 2026Q1: 2,675,509 shares; 2026Q2: 2,675,509 shares; 2026Q3: 2,475,509 shares 2,475,509$76.9M5.16%-200,000Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,034,582 shares; 2025Q1: 7,911,669 shares; 2025Q2: 7,911,669 shares; 2025Q3: 7,911,669 shares; 2025Q4: 7,911,669 shares; 2026Q1: 9,808,819 shares; 2026Q2: 9,808,819 shares; 2026Q3: 9,808,819 shares 9,808,819$70.9M4.76%0Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,470,214 shares; 2025Q1: 6,843,954 shares; 2025Q2: 6,843,954 shares; 2025Q3: 6,843,954 shares; 2025Q4: 8,508,641 shares; 2026Q1: 7,473,238 shares; 2026Q2: 7,085,249 shares; 2026Q3: 7,085,249 shares 7,085,249$61.2M4.11%0Timeline
COAGHEMAB THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,650,000 shares; 2026Q3: 1,650,000 shares 1,650,000$50.9M3.42%0Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,760,888 shares; 2025Q1: 2,760,888 shares; 2025Q2: 9,677,125 shares; 2025Q3: 9,677,125 shares; 2025Q4: 9,677,125 shares; 2026Q1: 9,677,125 shares; 2026Q2: 17,241,445 shares; 2026Q3: 21,209,188 shares 21,209,188$40.7M2.73%+3,967,743Timeline
FRNMFREENOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,365,459 shares 2,365,459$37.3M2.5%newTimeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,900,000 shares 1,900,000$30.6M2.05%newTimeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,111,910 shares; 2025Q1: 1,111,910 shares; 2025Q2: 1,111,910 shares; 2025Q3: 1,111,910 shares; 2025Q4: 7,171,910 shares; 2026Q1: 7,171,910 shares; 2026Q2: 7,171,910 shares; 2026Q3: 7,171,910 shares 7,171,910$23.9M1.6%0Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 563,859 shares; 2025Q3: 2,436,588 shares; 2025Q4: 7,967,454 shares; 2026Q1: 7,967,454 shares; 2026Q2: 7,967,454 shares; 2026Q3: 7,967,454 shares 7,967,454$23.1M1.55%0Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,249,069 shares; 2025Q1: 5,249,069 shares; 2025Q2: 5,249,069 shares; 2025Q3: 5,249,069 shares; 2025Q4: 5,249,069 shares; 2026Q1: 5,212,674 shares; 2026Q2: 4,437,731 shares; 2026Q3: 4,437,731 shares 4,437,731$18.8M1.26%0Timeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,485,638 shares; 2025Q1: 2,485,638 shares; 2025Q2: 2,485,638 shares; 2025Q3: 2,485,638 shares; 2025Q4: 2,485,638 shares; 2026Q1: 2,360,638 shares; 2026Q2: 2,075,639 shares; 2026Q3: 2,075,639 shares 2,075,639$10.8M0.73%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 983,500 shares; 2025Q1: 983,500 shares; 2025Q2: 583,500 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 141,234 shares; 2026Q2: 141,234 shares; 2026Q3: 141,234 shares 141,234$9.25M0.62%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,368,370 shares; 2025Q1: 3,368,370 shares; 2025Q2: 3,368,370 shares; 2025Q3: 3,368,370 shares; 2025Q4: 3,110,000 shares; 2026Q1: 3,110,000 shares; 2026Q2: 2,885,000 shares; 2026Q3: 1,312,000 shares 1,312,000$8.92M0.6%-1,573,000Timeline
RPIDRAPID MICRO BIOSYSTEMS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,434,560 shares; 2025Q1: 8,434,560 shares; 2025Q2: 8,434,560 shares; 2025Q3: 8,434,560 shares; 2025Q4: 8,434,560 shares; 2026Q1: 8,434,560 shares; 2026Q2: 8,434,560 shares; 2026Q3: 8,434,560 shares 8,434,560$8.69M0.58%0Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 664,021 shares; 2026Q2: 664,021 shares; 2026Q3: 664,021 shares 664,021$6.01M0.4%0Timeline
NAMSWNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 100,000 shares; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 99,999 shares; 2026Q1: 99,999 shares; 2026Q2: 99,999 shares; 2026Q3: 99,999 shares 99,999$1.26M0.08%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DNTHDIANTHUS THERAPEUTICS INC362,470$35.3Mshares
UPBUPSTREAM BIO INC600,949$4.16Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-462089 base2026-11-16